Completed PHASE4 INTERVENTIONAL 1-arm NCT00371150

Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection

A Study to Describe the Antiviral Effect of Entecavir (ETV) in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection Who Are Nucleoside-Naive

Sponsor: Bristol-Myers Squibb

Conditions Hepatitis B Infection

Interventions Entecavir

Updated 7 times since 2017 Last updated: Mar 22, 2012 Started: Nov 30, 2006 Primary completion: Mar 31, 2011 Completion: Mar 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00371150, this PHASE4 trial focuses on Hepatitis B Infection and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 7 times since 2006, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Belo Horizonte - Mg, Brazil , Belville, South Africa , Boston, United States , Campinas, Brazil , Chicago, United States , College Park, United States , Df, Mexico , Goodwood, South Africa , Guadalajara, Mexico , Miami, United States and 14 more locations